A-ADAM

In a new approach, genetic tools are used to introduce additional mitochondrial dysfunction into transgenic mice with pathogenic Alzheimer's disease proteins to model age-related metabolic deficits.

In an aging society, neurodegenerative diseases represent a significant medical and economic challenge for the healthcare system. Inadequate test systems in the early preclinical phase are a major stumbling block for efficient drug development. For the development of improved test systems, the EUREKA-Eurostars initiative of the European Union has approved funding for a joint project of the companies CeGaT GmbH, Tübingen, E-PHY-SCIENCE in Valbonne, France, and the NMI at the University of Tübingen. The linchpin is the mapping of a restricted energy balance of neurons, as observable in aging processes, in models for amyloid deposits observed in brains of patients with Alzheimer's disease. This combination will be used to develop new test systems for drug development and a new diagnostic test. The partners expect significant improvements over existing drug testing systems to accelerate the testing of new treatment options.